Ohta Shinichiro, Hirose M, Ishibashi H, Muro H
Department of Thoracic Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Kyobu Geka. 2007 Jul;60(7):519-22; discussion 522-5.
This study was done for the purpose of picking out the cases of poor prognosis from the peripherally located stage I adenocarcinoma of the lung.
Between January 1989 and December 2004, 235 patients with peripherally located stage I adenocarcinoma of the lung were resected curatively in our hospital. Relation between the 5-year survival rate and lymphatic and/or blood vessel invasion (from now on ductal invasion) was examined in these cases.
The 5-year survival rate was 99% in ly0v0 cases, 86% in ly0v1 cases, 85% in ly1v0 cases, 72% in ly1v1 cases, and 80% in ly2, 3 and/or v2, 3 (lyv 2-3) cases, respectively. Obviously the outcome of the cases without ductal invasion was good. The ratio of the cases without ductal invasion was 61% in stage IA, and 31% in stage IB. The 5-year survival rate was 99% in the cases without ductal invasion in stage IA, 100% in the cases without ductal invasion in stage IB, 90% in the cases with ductal invasion in stage IA, and 65% in the cases with ductal invasion in stage IB, respectively. And the 5-year survival rate without recurrence was 94% in the cases without ductal invasion in stage IA, 76% in the cases without ductal invasion in stage IB, 76% in the cases with ductal invasion in stage IA, and 54% in the cases with ductal invasion in stage IB, respectively.
Ductal invasion is significant prognostic factor in stage I adenocarcinoma of the lung. Adjuvant chemotherapy is unnecessary for the case without ductal invasion in stage IA. But we think that adjuvant chemotherapy is necessary for the case with ductal invasion in stage IA and for the case in stage IB, because there is much recurrence.
本研究旨在从周围型Ⅰ期肺腺癌中筛选出预后不良的病例。
1989年1月至2004年12月,我院对235例周围型Ⅰ期肺腺癌患者进行了根治性切除。研究了这些病例中5年生存率与淋巴管和/或血管侵犯(以下简称导管侵犯)之间的关系。
ly0v0病例的5年生存率为99%,ly0v1病例为86%,ly1v0病例为85%,ly1v1病例为72%,ly2、3和/或v2、3(lyv 2 - 3)病例为80%。显然,无导管侵犯病例的预后良好。无导管侵犯病例的比例在ⅠA期为61%,在ⅠB期为31%。ⅠA期无导管侵犯病例的5年生存率为99%,ⅠB期无导管侵犯病例为100%,ⅠA期有导管侵犯病例为90%,ⅠB期有导管侵犯病例为65%。ⅠA期无导管侵犯病例无复发的5年生存率为94%,ⅠB期无导管侵犯病例为76%,ⅠA期有导管侵犯病例为76%,ⅠB期有导管侵犯病例为54%。
导管侵犯是Ⅰ期肺腺癌的重要预后因素。ⅠA期无导管侵犯的病例无需辅助化疗。但我们认为,ⅠA期有导管侵犯的病例以及ⅠB期的病例需要进行辅助化疗,因为复发率较高。